Targeting Her-2/neu in breast cancer: as easy as this!

Oncology
Hamdy Azim, Hatem A Azim

Abstract

Her-2/neu-positive tumors account for approximately 20% of all breast cancer and these tumors carry poor prognosis. Trastuzumab and lapatinib are 2 agents that have gained FDA approval for treating Her-2/neu-positive breast cancer. Trastuzumab has been shown to improve all endpoints when added to chemotherapy compared to chemotherapy alone, both in the adjuvant and metastatic phases. The addition of lapatinib to capecitabine has recently been shown to improve time to progression in trastuzumab-refractory patients with unique activity against brain metastasis. In spite of their impressive results, a significant fraction of patients still develop either primary or secondary resistance, a fact that entails the discussion of possible mechanisms of resistance. Biomarkers including PTEN, p95HER2, IGF1R and others have been linked to response to Her-2/neu-targeting agents. In this article, we overview the Her-2/neu signaling pathways and how a better understanding of the different molecular aspects of this oncogene could serve in optimizing the use of Her-2/neu-targeting agents. We also discuss the preclinical and clinical data of these biomarkers that may guide clinicians in choosing the right drug whenever possible.

Citations

Jun 2, 2009·Nature Reviews. Clinical Oncology·Hatem A AzimAron Goldhirsch
Mar 19, 2014·Laboratory Investigation; a Journal of Technical Methods and Pathology·Kelly R PekalaMaureen A Gannon
Dec 20, 2008·Acta Oncologica·Fedro A Peccatori, Hatem A Azim
Oct 29, 2010·Expert Review of Clinical Immunology·Hatem A AzimFedro A Peccatori
Aug 26, 2010·Expert Review of Anticancer Therapy·Hatem A Azim, Martine J Piccart
May 23, 2013·Current Medical Research and Opinion·Mehmet A N SendurKadri Altundag
Jan 15, 2015·Current Medical Research and Opinion·Mehmet Ali Nahit ŞendurKadri Altundag
Sep 8, 2012·Current Medical Research and Opinion·Mehmet A N SendurKadri Altundag
Feb 14, 2013·Current Medical Research and Opinion·Baris BoyrazKadri Altundag
Aug 8, 2012·Bioorganic & Medicinal Chemistry·F Esra Onen-BayramRengul Cetin-Atalay
Nov 2, 2011·The Breast : Official Journal of the European Society of Mastology·Kamal S SainiMartine Piccart
May 11, 2010·Molecular Aspects of Medicine·Alexander Levitzki, Shoshana Klein
Sep 1, 2015·Critical Reviews in Oncology/hematology·María Teresa MartínezAna Lluch
Jul 31, 2009·Cancer Treatment Reviews·Hamdy AzimBernard Escudier
Dec 15, 2010·IUBMB Life·Verónica AndreoliJose Luis Bocco
Nov 30, 2010·The Breast : Official Journal of the European Society of Mastology·H A AzimF A Peccatori
Jul 1, 2016·Journal of Experimental & Clinical Cancer Research : CR·Alessandra FabiFrancesco Cognetti
Sep 18, 2017·Clinical & Experimental Metastasis·Joo Yeon Nam, Barbara J O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Michèle SabbahChristian Gespach
Current Opinion in Obstetrics & Gynecology
Ping TangGary H Lyman
© 2022 Meta ULC. All rights reserved